Trial Search Results

Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection

The purpose of this study is to determine whether shotgun sequencing technology, which can be used to detect donor DNA in recipient plasma, can be used as a rapid, accurate, non-invasive method to detect Acute Cellular Rejection (ACR) after heart transplantation. Currently, all heart transplant recipients undergo invasive heart biopsies to diagnose ACR. Thus, there is an ongoing need to monitor patients for the development of acute and chronic rejection, with the primary goal of non-invasive early detection and treatment to prevent organ damage.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Kaiser Foundation Research Institute

Stanford Investigator(s):

Eligibility


Inclusion Criteria:

   1. All ages of heart or lung transplant recipients

   2. Recipients of re-do heart or re-do lung transplants

Exclusion Criteria:

   1. Patients wait-listed for multiple organ transplantation (e.g. heart-kidney,
   heart-liver, heart and lung.)

   2. Unable or unwilling to return to Stanford for biopsy and follow-up procedures

   3. Followed by Palo Alto VA Hospital after transplant surgery (VA patients are
   transplanted at Stanford, but all subsequent clinical care is performed at VA
   hospitals)

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Recruiting